This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Teicher, B. A. Articles by Jacobs, J. L. Search for Related Content PubMed PubMed Citation Articles by Teicher, B. A. Articles by Jacobs, J. L.

Approaches to Defining the Mechanism of Enhancement by Fluosol-DA 20% with carbogen of Melphalan Antitumor Activity¹

Dana-Farber Cancer Institute, Boston, Massachusetts 02115

Fluosol-DA with carbogen (95% oxygen and 5% carbon dioxide) breathing can increase the efficacy of melphalan. Addition of Fluosol-DA to treatment with melphalan leads to a greater increase in tumor growth delay under conditions of air breathing and carbogen breathing than does the fat emulsion Intralipid. The ability of melphalan to kill tumor cells increased with dose over the range of drug examined. At the lower doses of drug there is some increase in tumor cell killing seen with the addition of carbogen breathing or Fluosol-DA and air breathing; however, at the highest dose of the drug this difference disappeared. Throughout the melphalan dosage range examined there is approximately 1 log greater tumor cell kill observed with the addition of Fluosol-DA and carbogen breathing compared to the drug treatment alone. There was no significant difference in the survival of bone marrow cells under any of the treatment conditions. Fluosol-DA itself with air or carbogen breathing produced no detectable cross-links in DNA from tumors treated in vivo. The cross-linking factors for melphalan with air or carbogen breathing and for melphalan plus Fluosol-DA and air breathing were similar; when carbogen breathing was added to the treatment combination, the cross-linking factor increased almost 3-fold. When melphalan was dissolved in Fluosol-DA, the melphalan moved quickly into the lipophilic perfluorochemical particles so that after 1 h 60% of the drug was in the perfluorochemical layer. At 24 h, 85–90% of the melphalan was sequestered in the perfluorochemical particles. The pharmacokinetics of [¹⁴C]melphalan alone, [¹⁴C]melphalan plus Fluosol-DA, and [¹⁴C]melphalan prepared in Fluosol-DA were studied in several tissues of FSaIIC fibrosarcoma-bearing mice. In general, the tissue absorption and distribution ts for melphalan were shortened in the presence of Fluosol-DA (except for kidneys). Shifting the ts for absorption and distribution to shorter times produces a much sharper and earlier peak in the drug exposure of the tumor. Fluosol-DA provides a relatively nontoxic means of increasing oxygen delivery to tumors and a therapeutically meaningful way of improving melphalan antitumor activity.

¹ This work was supported by National Cancer Institute grant 2PO1-CA1958909 (B. A. T.), grants from the American Cancer Society of New York and Alpha Therapeutics Co., Los Angeles CA 90032 (B. A. T.), and NIH fellowship 5F32-CA-07821-02 (S. A. H.).

² To whom requests for reprints should be addressed.

Received 7/14/86. Revised 10/24/86. Accepted 10/27/86.

This article has been cited by other articles:

				B. A. Teicher, V. Chen, C. Shih, K. Menon, P. A. Forler, V. G. Phares, and T. Amsrud Treatment Regimens Including the Multitargeted Antifolate LY231514 in Human Tumor Xenografts Clin. Cancer Res., March 1, 2000; 6(3): 1016 - 1023. [Abstract] [Full Text]

				B. A. Teicher, G. Ara, R. Herbst, V. J. Palombella, and J. Adams The Proteasome Inhibitor PS-341 in Cancer Therapy Clin. Cancer Res., September 1, 1999; 5(9): 2638 - 2645. [Abstract] [Full Text] [PDF]

				B. Teicher, T. Herman, S. Holden, Y. Wang, M. Pfeffer, J. Crawford, and E Frei 3rd Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo Science, March 23, 1990; 247(4949): 1457 - 1461. [Abstract] [PDF]